home / stock / allr / allr news


ALLR News and Press, Allarity Therapeutics Inc. From 04/09/24

Stock Information

Company Name: Allarity Therapeutics Inc.
Stock Symbol: ALLR
Market: NASDAQ

Menu

ALLR ALLR Quote ALLR Short ALLR News ALLR Articles ALLR Message Board
Get ALLR Alerts

News, Short Squeeze, Breakout and More Instantly...

ALLR - US Companies Moving the Markets, Morning edition
Tue, Apr 09, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 28.8% to $0.0515 on volume of 62,068,605 shares Laser Photonics Corporation (LASE) rose 172.7% to $3.9 on volume of 54,588,758 shares WiSA Technologies Inc. (WISA) fell 6.1% to $0.0217 on volume of 2...

ALLR - ALLR announced stock split 1-20

2024-04-08 09:02:03 ET Allarity Therapeutics, Inc. Common Stock (ALLR) announced stock split at a ratio of 1-for-20 on 2024-04-09 ... Full story available on KlickAnalytics.com

ALLR - Allarity Therapeutics to implement 1-for-20 reverse stock split

2024-04-04 09:28:02 ET More on Allarity Therapeutics Seeking Alpha’s Quant Rating on Allarity Therapeutics Read the full article on Seeking Alpha For further details see: Allarity Therapeutics to implement 1-for-20 reverse stock split

ALLR - Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of it...

ALLR - Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA ® and dovitinib is de-prioritized The Company has been ab...

ALLR - Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal exten...

ALLR - Allarity Therapeutics GAAP EPS of -$10.26

2024-03-08 08:44:33 ET More on Allarity Therapeutics Allarity Therapeutics appoints co-founder Thomas Jensen as interim CEO Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information f...

ALLR - Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive Advisor Reduced Net Loss from Operations by 50% and Reduced Net Loss by 26% Announced Data in December 2023 from Advanced Ovar...

ALLR - Expected US Company Earnings on Friday, March 8th, 2024

Genesco Inc. (GCO) is expected to report $2.66 for Q4 2024 Broadway Financial Corporation (BYFC) is expected to report for quarter end 2023-12-31 Oji Holdings Corporation ADR (OJIPY) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.54 for Q4 2024 GRI ...

ALLR - Allarity Therapeutics to Present at Biomarkers 2024

Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at...

Previous 10 Next 10